Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11

Correction to: Scientific Reports 10.1038/srep43941, published online 06 March 2017

In this Article, the U-20S Bicalutamide image in Figure 5C is a duplication of the KHOS control image in Figure 4F. The correct Figure 5 appears below as Figure 1.

Figure 1.

Effects of AR inhibitor bicalutamide in osteosarcoma cell lines. (A,B) Bicalutamide inhibits osteosarcoma cell viability. Cells were treated with bicalutamide or doxorubicin or the combination at the indicated concentrations. The relative sensitivity of each line was determined by MTT. (C,D) Bicalutamide inhibits colony formation units in osteosarcoma cell line U-2OS and KHOS. (E,F) Bicalutamide suppresses sphere formation of U-2OS and KHOS in three-dimensional culture. Spheroids formation of different cells after 7-day culture and the relative diameters compared with untreated cells. The assay was conducted in duplicate. *P < 0.05, **P < 0.01 (compared with control cells).